[Safety analysis of dust mite allergen for diagnosis and immunotherapy of asthma and rhinitis].
OBJECTIVE
To make a retrieval investigation of safety in using Dermatophagoides farinae extract in diagnosis and immunotherapy with patients of asthma and rhinitis.


METHODS
A questionnaire evaluation of the safety use of D. farinae extract (SMU-Df) during diagnosis and immunotherapy of patients from 1974 to 1995 was carried out.


RESULTS
A total of 8,46,342 injections were statistically analysed, among whom 142 systemic adverse reactions occurred involving urticaria 0.82@10000, severe attack of asthma 0.77@10000, anaphylactic shock 0.07@10000 (CL = 1.4-12.0/million), and angioedma 0.02@10000. The time of onset of systemic reactions of immediate type was < 30 min in 32 cases-times, and 1 h and 2 h in 6 cases-times; the time to onset of late response type was 3 h-48 h in 23 cases-times with highest incidence of severe asthmatic attacks. The systemic reactions occurred in 18 subjects during skin test, in 96 cases-times during increasing dose phase, and in 14 cases-times during. Among them 6 cases were of anaphylactic shock, and none of it after emergency treatment. The major cause of manifestation of systemic reactions for 41 cases after immunotherapy with SMU-Df extract was due to over dosage errors.


CONCLUSIONS
The application of SMU-Df extract in skin test and immunotherapy of asthma and rhinitis sensitive to mite for the past 22 years in this country indicated that the efficacy and safety have been high.
Wen
T
T
Medical Acarology Laboratory, Shanghai Medical University, Shanghai 200032.
Cai
Y
Y
Chen
X
X
Xiang
L
L
Wang
B
B
Zhuang
Y
Y
D000485:Allergens / Q000627:therapeutic use*; D000707:Anaphylaxis / Q000139:chemically induced; D000818:Animals; D001249:Asthma / Q000628:therapy*; D001986:Bronchial Spasm / Q000139:chemically induced; D040002:Dermatophagoides pteronyssinus; D003888:Desensitization, Immunologic / Q000379:methods; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology; D007167:Immunotherapy / Q000009:adverse effects*; D008925:Mites / Q000737:chemistry; D039981:Pyroglyphidae / Q000737:chemistry*; D012120:Respiration Disorders / Q000139:chemically induced; D012220:Rhinitis / Q000628:therapy*; D012221:Rhinitis, Allergic, Perennial; D012449:Safety
D000485:Allergens